doi: 10.1111/bjh.17627.
Epub 2021 Jun 24.
Impact of t(11;14) as a sole and concomitant abnormality on outcomes in multiple myeloma
Affiliations
- PMID: 34165783
- DOI: 10.1111/bjh.17627
Item in Clipboard
Impact of t(11;14) as a sole and concomitant abnormality on outcomes in multiple myeloma
Br J Haematol.
2021 Oct.
No abstract available
Similar articles
-
Natural history of multiple myeloma patients refractory to venetoclax: A single center experience.Am J Hematol. 2021 Mar 1;96(3):E68-E71. doi: 10.1002/ajh.26064. Epub 2020 Dec 28. Am J Hematol. 2021. PMID: 33275813 No abstract available.
-
Deep and sustained response after venetoclax therapy in a patient with very advanced refractory myeloma with translocation t(11;14).Haematologica. 2017 Mar;102(3):e112-e114. doi: 10.3324/haematol.2016.160408. Epub 2017 Jan 5. Haematologica. 2017. PMID: 28057737 Free PMC article. No abstract available.
-
Secondary plasma cell leukaemia treated with single agent venetoclax.Br J Haematol. 2020 Aug;190(4):e242-e245. doi: 10.1111/bjh.16858. Epub 2020 Jun 11. Br J Haematol. 2020. PMID: 32525557 No abstract available.
-
Cyclin D1 as the putative bcl-1 oncogene.Curr Top Microbiol Immunol. 1995;194:347-53. doi: 10.1007/978-3-642-79275-5_40. Curr Top Microbiol Immunol. 1995. PMID: 7895508 Review. No abstract available.
-
Venetoclax in combination with carfilzomib and dexamethasone in relapsed/refractory multiple myeloma harboring t(11,14)(q13;q32): two case reports and a review of the literature.J Med Case Rep. 2020 Apr 23;14(1):54. doi: 10.1186/s13256-020-02376-y. J Med Case Rep. 2020. PMID: 32321588 Free PMC article. Review.
Cited by
-
Navigating the Prognostic Complexity of IgH Cytogenetic Abnormalities in Multiple Myeloma Among Diverse IgH Cytogenetic Abnormalities-Involved High-Risk Stratifications.Cancer Med. 2025 Sep;14(17):e71152. doi: 10.1002/cam4.71152. Cancer Med. 2025. PMID: 40859868 Free PMC article.
-
Treatment patterns and outcomes according to cytogenetic risk stratification in patients with multiple myeloma: a real-world analysis.Blood Cancer J. 2022 Mar 23;12(3):46. doi: 10.1038/s41408-022-00638-0. Blood Cancer J. 2022. PMID: 35322025 Free PMC article.
-
T(11;14) with multiple myeloma: Standard risk survival but slow and poor response.Ann Hematol. 2024 Dec;103(12):5573-5581. doi: 10.1007/s00277-024-06026-x. Epub 2024 Oct 2. Ann Hematol. 2024. PMID: 39358544
-
Is t(11;14) in newly diagnosed multiple myeloma a favorable outcome in the novel agent era?Blood Res. 2025 Feb 6;60(1):11. doi: 10.1007/s44313-025-00056-8. Blood Res. 2025. PMID: 39913013 Free PMC article.
-
The Role of t(11;14) in Tailoring Treatment Decisions in Multiple Myeloma.Cancers (Basel). 2023 Dec 13;15(24):5829. doi: 10.3390/cancers15245829. Cancers (Basel). 2023. PMID: 38136374 Free PMC article. Review.
References
-
- Landgren O, Kyle RA, Pfeiffer RM, Katzmann JA, Caporaso NE, Hayes RB, et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood. 2009;113(22):5412-7.
-
- Avet-Loiseau H, Garand R, Lodé L, Harousseau J-L, Bataille R; Intergroupe Francophone du Myélome. Translocation t(11;14)(q13;q32) is the hallmark of IgM, IgE, and nonsecretory multiple myeloma variants. Blood. 2003;101(4):1570-1.
-
- Kumar SK, Harrison SJ, Cavo M, de la Rubia J, Popat R, Gasparetto C, et al. Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol [Internet]. 2020 Oct 29 [cited 2020 Nov 8]; Available from: http://www.sciencedirect.com/science/article/pii/S1470204520305258
-
- Fonseca R, Blood EA, Oken MM, Kyle RA, Dewald GW, Bailey RJ, et al. Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients. Blood. 2002;99(10):3735-41.
-
- Kaufman GP, Gertz MA, Dispenzieri A, Lacy MQ, Buadi FK, Dingli D, et al. Impact of cytogenetic classification on outcomes following early high-dose therapy in multiple myeloma. Leukemia. 2016;30(3):633-9.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
